未成熟血小板比例对冠心病双联抗血小板治疗6个月的出血风险的预测价值

doi:10.3969/j.issn.1001-8131.2026.05.010

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (440 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the predictive value of immature platelet fraction(IPF)for bleeding risk in patients with coronary artery disease(CAD)receiving 6-month dual antiplatelet therapy(DAPT). Methods A prospective study was conducted.A total of 213 patients with acute coronary syndrome or stable CAD after percutaneous coronary intervention were consecutively enrolled.All patients received dual antiplatelet therapy,and IPF was measured.Telephone follow-up was performed 6 months after discharge to collect data on bleeding events.The correlations between various factors and bleeding events were examined and a multivariate Logistic regression analysis was used to construct a predictive model for bleeding events. Results A total of 84 patients(39.4%)experienced bleeding events during the 6-month DAPT period,primarily manifesting as mucocutaneous bleeding.IPF was negatively correlated with bleeding risk at 6 months of DAPT(OR=0.703).Bleeding risk were also correlated with renal function,inflammation,left main coronary artery disease and ticagrelor use. Conclusion IPF can predict bleeding risk at 6 months in patients with CAD receiving DAPT.

Key words： Immature platelet fraction Coronary artery disease Dual antiplatelet therapy Bleeding

Received: 01 April 2026

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wu Xiaoying
	Nie Ruqiong

Cite this article:

Wu Xiaoying,Nie Ruqiong. The Predictive Value of Immature Platelet Fraction for the Bleeding Risk during the 6-month Dual Antiplatelet Therapy for Coronary Artery Disease[J]. journal1, 2026, 46(5): 35-37.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2026.05.010 OR http://www.hrbyybjb.org.cn/EN/Y2026/V46/I5/35

[1] 中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.
[2] Levine G N,Jeong Y H,Goto S,et al.World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI[J].Global Heart,2014,9(4):457-67.
[3] Kamath S,Blann A D,Lip G Y.Platelet activation: assessment and quantification[J].European Heart Journal,2001,22(17):1561-71.
[4] Freynhofer M K,Iliev L,Bruno V,et al.Platelet turnover predicts outcome after coronary intervention[J].Thrombosis and Haemostasis,2017,117(5):923-33.
[5] Rechcinski T,Jasinska A,Forys J,et al.Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention[J].Cardiol J,2013,20(5):491-8.
[6] Mehran R,Rao S V,Bhatt D L,et al.Standardized bleed-ing definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium[J].Circulation,2011,123(23):2736-47.
[7] Alexopoulos D,Xanthopoulou I,Deftereos S,et al.Conte-mporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention:1-year outcomes from the GReek AntiPlatElet(GRAPE)Registry[J].Journal of Thrombosis and Haemostasis:JTH,2016,14(6):1146-54.
[8] Bahou W F.Genetic dissection of platelet function in health and disease using systems biology[J].Hematology/oncology clinics of North America,2013,27(3):443-63.
[9] Guthikonda S,Alviar C L,Vaduganathan M,et al.Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease[J].Journal of the American College of Cardiology,2008,52(9):743-9.
[10] Dusse L M,Freitas L G.Clinical applicability of re-ticulated platelets[J].Clin Chim Acta,2015,439:143-7.
[11] 张岩,王聪霞,刘晓唤,等.网织血小板与早发冠心病PCI术后远期预后的相关性[J].西安交通大学学报,2018,39(3):327-31.